Stock 6550 POLARIS GROUP
Add to a list
To use this feature you must be a member
Log inSign up

News Polaris Group

Equities

6550

KYG7171A1085

End-of-day quote Taiwan S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
73.3 TWD -0.41% Intraday chart for Polaris Group +1.81% -3.04%
May. 15 Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA CI
May. 14 Polaris Group Announces Change of the Member of Compensation Committee CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA
CI
Polaris Group Announces Change of the Member of Compensation Committee
CI
Polaris Group Announces Change of the Member of Audit Committee
CI
Polaris Group acquired an additional unknown stake in Genovior Biotech Corporation for TWD 2 billion.
CI
Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth
GL
Polaris Group Announces the Appointment of K Evin Wu
CI
Polaris Group Announces Chief Executive Officer Changes, Effective December 21, 2023
CI
Polaris Group agreed to acquire additional unknown stake in Genovior Biotech Corporation for TWD 2 billion.
CI
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)
GL
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)
AQ
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study
GL
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20 in Phase II Clinical Trial for NASH at Chang Gung Memorial Hospital, Linkou, Taiwan
CI
Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma
GL
Polaris Group Initiates Rolling Submission of Biologic License Application for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma
CI
Polaris Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Polaris Group announced a financing transaction
CI
Polaris Group Appoints K.C. Tsai as Compensation Committee Member
CI
TDW HK Limited announced that it has received $17 million in funding from Polaris Group
CI
Polaris Group Announces Resignation of TAI, JANG-HUEI as Audit Committee and Remuneration Committee Member
CI
Polaris Group Announces of Resignation of TAI, JANG-HUEI as Independent Director
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6550 Stock
  4. News Polaris Group